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Background/Purpose: The incidence of breast cancer is on the rise in Asia including 
Hong Kong. 40% of the breast cancer patients are diagnosed before age of 50 in Hong 
Kong. From clinical aspect, it is important to distinguish patients with inherited predis-
position to breast cancer from sporadic cases, particularly in early-onset patients ( < 45 
years old). BRCA1/2 have been widely investigated and frequently implicated in familial 
predisposition to breast cancer. Conventional Sanger sequencing has long been used and 
proved to be a reliable method, although it is relatively labour intensive and expensive. 
Methods: An alternative high efficiency method is much desired, thus more patients 
will benefit from screening. Harnessing the advantage of Polymerase Chain Reaction 
(PCR) array and next generation sequencing (NGS), we expand the BRCA gene panel 
to include TP53 and PTEN. The sensitivity of the NGS platform was validated by over 
hundred Sanger detectable mutations. We have also provided a solution to overcome 
the challenges in the analysis of homopolymer regions by in-house bioinformatics al-
gorithm. 
Results: The NGS approach to mutation detection was applied to 464 high-risk index 
patients. Altogether 1,092 index patients were examined by either Sanger or NGS ap-
proach, germline mutation has been identified in 10% of the families. Overall, 24.1%, 
19.4% and 17% of the mutation carriers presented with multiple cancers, triple negative 
breast cancer and family history of breast and/or ovarian cancer respectively. 
Conclusion: These findings may provide information for adaptation of NGS in the 
diagnostic molecular pathology service and revolutionize laboratory strategies for mu-
tation screening. 
